Un cambio radical en el modo de pensar las enfermedades | 02 AGO 19

¿Una nueva era en el manejo del asma?

Redefinición de las enfermedades de las vías aéreas que puede dar lugar a nuevas guías sobre el asma, con nuevos medicamentos biológicos
Autor/a: Ian D Pavord, Richard Beasley, Alvar Agusti, Gary P Anderson y colaboradores Asthma Commission: The Lancet: September 11, 2017
INDICE:  1. Página 1 | 2. Referencias bibliográficas | 3. Página 3
Referencias bibliográficas

1 Kola I, Bell J. A call to reform the taxonomy of human disease. Nat Rev Drug Discov 2011; 10: 641–42.

2 Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958; 2: 1245–47.

3 Hilvering B, Xue L, Pavord ID. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis 2015; 9: 135–45.

4 Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3: 831–44.

5 Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997;52: 498–501.

6 Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess airway diseases. Lancet 2008; 372: 1017–19.

7 Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin  Immunol 2015; 135: 299–310.

8 Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65.

9 Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol 2014; 133: 39–41.

10 Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–21.

11 Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483–94.

12 Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–59.

13 Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006; 117: 1230–32.

14 Woolcock A, Rubinfeld AR, Seale JP, et al. Thoracic society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust 1989; 151: 650–53.

15 Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990; 85: 1098–111.

16 Guidelines for management of asthma in adults: I—Chronic persistent asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King’s Fund Centre, National Asthma Campaign. BMJ 1990; 301: 651–53.

17 Warner JO, Gotz M, Landau LI, et al. Management of asthma: a consensus statement. Arch Dis Child 1989; 64: 1065–79.

18 Pappworth ME. A primer of medicine, 5th edn. Oxford: Butterworth-Heinemann, 1984.

19 Ebmeier S, Thayabaran D, Braithwaite I, Benamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet 2017; published online Aug 7. DOI:10.1016/S0140-6736(17)31448-4.

20 Martinez FD, Vercelli D. Asthma. Lancet 2013; 382: 1360–72. 21 Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J 2015; 45: 1197–207.

22 Rosenthal M. CON: encouraging resistance to rule-based medicine is essential to improving outcomes. Thorax 2015; 70: 112–14.

23 Ciba Guest Symposium. Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions. Thorax 1959; 14: 13.

24 A plea to abandon asthma as a disease concept. Lancet 2006; 368: 705. 25 Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–24.

26 Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906–13.

27 Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of  fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983–90.

28 Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–84.

29 Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–66.

30 Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomized placebo-controlled studies. Thorax 2015; 70: 748–56.

31 Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088–98. 32 Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804–13.

33 Floyer J. A treatise of the asthma. London: R. Wilkins, 1698.

34 Salter HH. Asthma, its pathology and treatment. London: John Churchill, 1860.

35 Osler W. The principles and practice of medicine. New York: Appleton, 1894.

36 Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 02-3659. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002.

37 Global Initiative for Asthma. 2017 GINA report, global strategy for asthma management and prevention. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-andprevention/(accessed June 5, 2017).

38 Cohen SG. Sir John Floyer (1649–1734) British physician and pioneer clinical investigator. Allergy Proc 1995; 16: 328–29.

39 Sakula A. Henry Hyde Salter (1823–71): a biographical sketch. Thorax 1985; 40: 887–88.

40 Rackemann FM. A clinical survey of 1074 patients with asthma followed for two years. J Lab Clin Med 1927; 12: 1185–97.

41 Hutchinson J. Thorax. In: Todd RB, ed. The cylopaedia of anatomy and physiology. London: Longmans, 1852: 1016–87.

42 Tiffeneau R, Drutel P. Etude des facteurs alveolaires et bronchiques de la ventilation pulmonaire. J Fr Med Chir Thorac 1949; 3: 401–31.

43 Fingleton J, Weatherall M, Beasley R. Bronchodilator responsiveness: interpret with caution. Thorax 2012; 67: 667–68.

44 Controlled trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet 1956; 271: 803–06.

45 Brown HM. How the first effective inhaled corticosteroid was almost discarded as useless. Ann Allergy Asthma Immunol 2007; 98: 602–03.

46 Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. BMJ 1972; 1: 585–90.

47 Selander PER. Asthmatic Symptoms in the First Year of Life. Acta Paediatr 1960; 49: 265–69.

48 Fry J. “Acute Wheezy Chests”. BMJ 1961; 1: 227–32.

49 Sporik R, Holgate ST, Cogswell JJ. Natural history of asthma in childhood--a birth cohort study. Arch Dis Child 1991; 66: 1050–53.

50 Cogswell JJ. The wheezy child. Practitioner 1976; 217: 371–76.

51 Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014; 69: 805–10.

52 Silverman M. Out of the mouths of babes and sucklings: lessons from early childhood asthma. Thorax 1993; 48: 1200–04.

53 Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ, and the The Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med 1995; 332: 133–38.

54 Savenije OE, Granell R, Caudri D, et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. J Allergy Clin Immunol 2011; 127: 1505–12, e14.

55 Kerkhof M, Boezen HM, Granell R, et al. Transient early wheeze and lung function in early childhood associated with chronic obstructive pulmonary disease genes. J Allergy Clin Immunol 2014; 133: 68–76, e1–4.

56 Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Ann Allergy Asthma Immunol 2003; 91: 398–404.

57 Semic-Jusufagic A, Belgrave D, Pickles A, et al. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-based birth cohort study. Lancet Respir Med 2014; 2: 621–30.

58 Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003; 349: 1414–22.

59 Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Trajectories of lung function during childhood. Am J Respir Crit Care Med 2014; 189: 1101–09.

60 Tromp II, Kiefte-de Jong JC, Lebon A, et al. The introduction of allergenic foods and the development of reported wheezing and eczema in childhood: the Generation R study. Arch Pediatr Adolesc Med 2011; 165: 933–38.

61 Smith JA, Drake R, Simpson A, Woodcock A, Pickles A, Custovic A. Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med 2008; 177: 1358–63.

62 Crestani E, Guerra S, Wright AL, Halonen M, Martinez FD. Parental asthma as a risk factor for the development of early skin test sensitization in children. J Allergy Clin Immunol 2004; 113: 284–90.

63 Weitzman M, Gortmaker S, Walker DK, Sobol A. Maternal smoking and childhood asthma. Pediatrics 1990; 85: 505–11.

64 Tollanes MC, Moster D, Daltveit AK, Irgens LM. Cesarean section and risk of severe childhood asthma: a population-based cohort study. J Pediatr 2008; 153: 112–16.

65 Seidman DS, Laor A, Gale R, Stevenson DK, Danon YL. Is low birth weight a risk factor for asthma during adolescence? Arch Dis Child 1991; 66: 584–87.

66 Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988; 319: 1112–17.

67 Turner SW, Palmer LJ, Rye PJ, et al. The relationship between infant airway function, childhood airway responsiveness, and asthma. Am J Respir Crit Care Med 2004; 169: 921–27.

68 Clarke JR, Salmon B, Silverman M. Bronchial responsiveness in the neonatal period as a risk factor for wheezing in infancy. Am J Respir Crit Care Med 1995; 151:  434–40.

69 Palmer LJ, Rye PJ, Gibson NA, Burton PR, Landau LI, Lesouef PN. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am J Respir Crit Care Med 2001; 163: 37–42.

70 Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med 2012; 185: 1183–89.

71 Ege MJ, Mayer M, Normand A-C, et al, and the GABRIELA Transregio 22 Study Group. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011; 364: 701–09.

72 Langley SJ, Goldthorpe S, Craven M, Morris J, Woodcock A, Custovic A. Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 2003; 112: 362–68.

73 Simpson A, John SL, Jury F, et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med 2006; 174: 386–92.

74 Custovic A, Lazic N, Simpson A. Pediatric asthma and development of atopy. Curr Opin Allergy Clin Immunol 2013; 13: 173–80.

75 Simpson A, Tan VY, Winn J, et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care Med 2010; 181: 1200–06.

76 Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354: 1985–97.

77 Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354: 1998–2005.

78 Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, for the IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368: 754–62.

79 Saglani S, Payne DN, Zhu J, et al. Early detection of airway wallremodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med 2007; 176: 858–64.

80 Green RH, Brightling CE, McKenna S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 2006; 27: 1144–51.

81 Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–7: a further case-control study. Thorax 1991; 46: 105–11.

82 Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; 1: 917–22.

83 Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105: 883–90.

84 Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604–10.

85 Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806–17.

86 Levy ML, Winter R. Asthma deaths: what now? Thorax 2015: 70: 209–10.

87 Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J 2009; 34: 1052–59.

88 Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24.

89 Pauwels RA, Lofdahl CG, Postma DS, et al, and the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11.

90 Beasley R, Perrin K, Weatherall M, Wijesinghe M. Call for withdrawal of LABA single-therapy inhaler in asthma. Lancet 2010; 376: 750–51.

91 Beasley R, Keil U, von Mutius E, et al, and the The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225–32.

92 Global Asthma Network. The global asthma report 2014. http://www. globalasthmareport.org (accessed Feb 26, 2017).

93 To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12: 204.

94 Kauppi P, Linna M, Martikainen J, Makela MJ, Haahtela T. Follow-up of the Finnish Asthma Programme 2000-2010: reduction of hospital burden needs risk group rethinking. Thorax 2013; 68: 292–93.

95 Djukanović R, Harrison T, Johnston SL, et al, and the INTERCIA Study Group. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014; 190: 145–54.

96 Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121: 1051–57.

97 Joyce DP, Chapman KR, Kesten S. Prior diagnosis and treatment of patients with normal results of methacholine challenge and unexplained respiratory symptoms. Chest 1996; 109: 697–701.

98 Shaw D, Green R, Berry M, et al. A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 2012; 21: 283–87.

99 Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–65.

100 Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761–67.

101 Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719–28.

102 Pavord I, Bush A. Two Lovely Black Eyes; Oh, what a surprise! Thorax 2015; 70: 609–10.

103 Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683–91.

104 Wain LV, Shrine N, Miller S, et al, and the UK Brain Expression Consortium (UKBEC), and the OxGSK Consortium. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med 2015; 3: 769–81.

105 Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010; 65: 370. 106 Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875–79.

107 Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132: 821–27, e1–5.

108 Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435–42.

109 Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005;172: 453–59.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022